Zymeworks Inc.

As a publicly traded company, Zymeworks' board of directors oversees corporate strategy, while CEO Kenneth Galbraith leads executive decisions. The scientific direction is shaped by the founding team and chief scientific officer.

Zymeworks developed its bispecific antibody platform internally over two decades. The Azymetric platform is its core intellectual property, enabling precise engineering of antibodies that can bind two targets simultaneously.

Zymeworks is a publicly traded biotechnology company, not a family office or venture firm. However, its long-term R&D focus and partnership-heavy business model resemble the patient capital approach of a family office.

Zymeworks is an operating biotech company; it does not deploy capital as an investment manager. Its partnerships with Jazz Pharmaceuticals and Daiichi Sankyo involve upfront payments, equity investments, and milestone revenues.

Zymeworks focuses on preclinical and clinical-stage drug development. It advances its own pipeline to early-phase clinical trials before seeking partners for late-stage development and commercialization.

Zymeworks concentrates exclusively on oncology and immuno-oncology. It does not engage in other therapeutic areas such as neurology, infectious disease, or rare diseases.

Zymeworks is a standalone public company (NYSE: ZYME). It has subsidiary operations in the U.S. through Zymeworks USA Inc. and historically had a collaboration with Eli Lilly, which was terminated.